Pharmaceutical

ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction

New data provides more evidence on choosing the ideal approach for prescription of beta blockers for myocardial infarction.

Sep 4, 2024 - 04:00
ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction
New data provides more evidence on choosing the ideal approach for prescription of beta blockers for myocardial infarction.
Read the original article

Tags:

Previous Article

Syntekabio and Enamine partner for AI-based drug development

Next Article

UAE MoHAP and Novo Nordisk partner for obesity management

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Why the Importer of Record (IoR) is vital in the clinical supply chain ­­

Why the Importer of Record (IoR) is vital in the clinic...

Sep 4, 2024

Astellas invests $50m in Poseida’s CAR-T cell therapy

Astellas invests $50m in Poseida’s CAR-T cell therapy

Aug 8, 2023

FDA accepts Alpha Cognition’s NDA for Alzheimer’s disease

FDA accepts Alpha Cognition’s NDA for Alzheimer’s disease

Dec 8, 2023